XCL1 and neoplasm: The fused EV platform AS16‐EL@MPLA/p‐FX reprograms tumor cells into cytokine‐producing factories that continuously secrete XCL1 and FLT3L to recruit and differentiate cDC1s, while embedded MPLA activates them through TLR4 signaling and AS16 prevents their exhaustion, thereby enhancing antitumor immunity and establishing durable immune memory against tumor progression, metastasis, and recurrence.